Palbociclib has successfully induced cellular senescence in melanoma, liposarcoma, gastric cancer, and hepatocellular carcinoma by inhibiting the mammalian target of rapamycin (mTOR) signaling pathway [84,85]. This evidence concerns the gene MTOR and hepatocellular carcinoma.